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Abstract
We report the ﬁrst outbreak caused by colistin-resistant Klebsiella
pneumoniae producing KPC-3 carbapenamase in two Italian
hospitals. This spread occurred in 1 month, and was caused by
eight colistin-resistant and carbapenem-resistant Klebsiella
pneumoniae isolates from eight patients. A further three isolates
were obtained from the intestinal tract and pharyngeal colonization.
All isolates were multidrug-resistant (MDR), including being resistant
to colistin, but they were susceptible to gentamicin and tigecycline.
PCR detection showed that all isolates harboured the blaKPC-3 gene
associated with blaSHV-11, blaTEM-1 and blaOXA-9. All K. pneumoniae
isolates, genotyped by pulsed-ﬁeld gel electrophoresis and
multilocus sequence typing, belonged to the same sequence type
(ST)258 clone. From our data and a review of the international
literature, K. pneumoniae ST258 seems to be the most widespread
genetic background for KPC dissemination in Europe.
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Among class A carbapenemases, KPC enzymes have
eclipsed all other major groups i.e. GES, SME, IMI and
NMC-A, to become the dominant enzymes, with endemic
behaviour and/or outbreaks in 27 states in the USA, as
well as in China, South America and Israel [1–5]. Since
2005, KPC-positive strains have been isolated in Europe:
in France, Germany, the UK, Greece and, more recently,
Italy [6–10].
Until very recently, KPC enzymes had only been found in
Enterobacteriaceae; however, they have now been character-
ized from Pseudomonas aeruginosa [11,12] and from several
Acinetobacter spp. strains [13].
In 2009–2010 in Italy, a few reports outlined the isolation
of two KPC variants, i.e. multidrug-resistant (MDR) KPC-2
and KPC-3, belonging to ST258, and susceptible only to
colistin, tigecycline and gentamicin [14,15].
We report a hospital outbreak, occurring between 19
August and 27 October 2010, caused by eight colistin-resis-
tant and carbapenem-resistant Klebsiella pneumoniae isolates
from eight patients in two different hospitals in Catania
(University and Vittorio Emanuele hospitals). A further three
isolates were obtained from the intestinal tract and pharyn-
geal colonization of three patients: these strains were
included in the study for their characterization.
The ﬁrst KPC-producing K. pneumoniae isolate was
obtained from abdominal drainage ﬂuid of a patient aged
84 years admitted to the intensive-care unit (ICU) of the
University Hospital and coming from another Sicilian hospital.
It was not possible to establish whether patient 1 could be
considered the index case, because an active surveillance cul-
ture system was not in place at the time of admission. In the
month after the ﬁrst isolate had been obtained, there was a
rapid intrahospital outbreak of these strains isolated from
seven patients in different wards (ICU, surgery, internal
medicine, transplant unit and paediatric haematology).
Subsequently, after 20 days, one case of bloodstream infec-
tion in the nephrology ward of Vittorio Emanuele Hospital
occurred, in one patient coming from the ICU of the Univer-
sity Hospital, where three other cases were previously
conﬁrmed.
The rapid spread of K. pneumoniae with this MDR resis-
tance pattern in such a short period caused concern, and
activated an investigation to determine the possible source
of this outbreak, to establish the increasing risk of transmis-
sion, and to start the infection containment procedure.
In fact, infection control measures, including undertaking
contact precautions, segregating infected/colonized patients,
and using dedicated staff and equipment as much as possible,
were implemented at that time [16].
Therefore, all patients included in our study, after infec-
tion, were screened weekly for colonization, by the use of
pharyngeal and rectal swabs, with a previously published
method in which the culture was grown in the presence of a
10-lg disk of imipenem and subsequently plated on MacCon-
key agar [17]: only three of eight patients were colonized,
but it was not possible to establish whether they were colo-
nized at the time of admission. The patients remained colo-
nized until discharge. In all cases, targeted combination
treatment, including gentamicin plus tigecycline and/or carba-
penems and/or an anti-Gram-positive drug, was used. With
regard to the outcomes, seven patients are still alive, and
one died from causes not related to the infection.
The identiﬁcation and antimicrobial susceptibility testing
of 11 isolates was preliminarily performed with the Vi-
tek 2 system (bioMerieux, Marcy l’Etoile, France). The
identiﬁed species level was centrally reconﬁrmed with the
API 20E system (Bio Merieux), and the MICs were deter-
mined with a microdilution method, interpreted according
to EUCAST guidelines [18]. These isolates were resistant
to almost all antibiotics, including colistin (MIC 64 mg/L)
TABLE 1. Clinical characteristics of patients and antibiotic susceptibility of KPC-3-producing Klebsiella pneumoniae
Patients Date Hospital Ward Specimens
MIC (mg/L)
IPM MEM DOR ETP CEF CAZ CTX TZP TG CT CIP GM
1 19 August 2010 University ICU Abdominal drainage 32 64 64 >128 128 >64 >64 >512 1 16 128 2
2 31 August 2010 University Surgery CVC 64 64 64 >128 >128 >64 >64 >512 1 32 128 2
3 10 September 2010 University ICU Bloodstream 64 128 64 128 >128 >64 >64 >512 1 16 128 2
4 19 September 2010 University ICU Bronchial aspirate 64 64 32 >128 >128 >64 >64 >512 1 32 128 2
5 20 September 2010 University Internal Medicine Urine 64 64 64 >128 >128 >64 >64 >512 1 8 256 2
6 23 September 2010 University Transplant Sputum 32 64 128 128 128 >64 >64 >512 1 64 128 2
7 26 September 2010 University Paediatric Haematology Bloodstream 64 64 256 >128 128 >64 >64 >512 1 32 128 2
8 19 October 2010 VE Nephrology Bloodstream 128 512 64 512 512 >512 256 >512 1 8 256 2
3a 20 October 2010 University ICU Pharyngeal swab 32 64 64 128 128 >64 >64 >512 1 32 128 2
7a 26 October 2010 University Paediatric Haematology Rectal swab >512 >512 64 >512 256 >512 256 >512 1 8 128 2
4a 27 October 2010 University ICU Rectal swab 64 512 64 512 512 >512 256 >512 1 16 128 2
IPM, imipenem; MEM, meropenem; DOR, doripenem; ETP, ertapenem; CEF, cefepime; CAZ, ceftazidime; CTX, cefotaxime; TZP, piperacillin–tazobactam; TG, tigecycline; CT,
colistin; CIP, ciproﬂoxacin; GM, gentamicin; VE, Vittorio Emanuele; CVC, central venous catheter; ICU, intensive-care unit.
aColonization.
CMI Research Notes 1445
ª2011 The Authors
Clinical Microbiology and Infection ª2011 European Society of Clinical Microbiology and Infectious Diseases, CMI, 17, 1435–1447
and carbapenems. All isolates were susceptible only to
tigecycline (MIC 1 mg/l) and gentamicin (MIC 2 mg/L); see
Table 1.
Analysis of b-lactamase genes by PCR and sequencing
revealed the presence of blaKPC-3, blaSHV-11, blaTEM-1 and
blaOXA-9 in all isolates, whereas genes encoding other
enzymes (CTX type and VIM type) were not detected.
All K. pneumoniae isolates, genotyped after XbaI diges-
tion by pulsed-ﬁeld gel electrophoresis, belonged to the
same clone, as they were indistinguishable from each other
(100% identity) according to the criteria described previ-
ously by Tenover et al. [19], and with the multilocus
sequence typing (MLST) scheme, according to the protocol
described on the K. pneumoniae MLST website (http://
www.pasteur.fr/recherche/genopole/PF8/mlst/Kpneumoniae.
html) [20], all isolates were attributed to sequence type
(ST)258.
This study reports, for the ﬁrst time, an outbreak of
KPC-3 colistin-resistant K. pneumoniae infection in Italy.
However, in our country, there are only a few reports on
KPC isolation (all colistin-susceptible). The ﬁrst case
detected was from an inpatient with a complicated intra-
abdominal infection in 2009 [10]; subsequently, KPC-3
K. pneumoniae ST258 was found in Palermo [14] in 13
patients. Another isolate of KPC K. pneumoniae was identi-
ﬁed in Rome, but the strain was not characterized [15],
and a KPC-2 K. pneumoniae isolate was characterized in
Switzerland from a Sicilian patient [21]. In all but one of
these cases, the strains were ST258, and were susceptible
to gentamicin, tigecycline and colistin.
Our isolates were colistin-resistant KPC-3 ST258
K. pneumoniae; colistin resistance is still uncommon among
KPC producers (an outbreak of KPC-2 ST258 was recently
described in Greece), and has been attributed mainly to the
modiﬁcation of lipid A of the outer membrane and the pres-
ence of an efﬂux pump [22,23]. In our study, the exact
mechanism of colistin resistance was not investigated.
Even though, in our cases, all patients were cured, we
observed that three of them tended to remain colonized
until their discharge. It was not possible to continue the sur-
veillance of these patients after their discharge from hospital.
The other ﬁve patients were negative for all of the surveil-
lance time.
All of these observations, together with the awareness of
the limited therapeutic options for treatment these infec-
tions, lead to the alarming conclusion that we need urgent
action to slow down and control the worldwide and epi-
demic spread of carbapenamase-producing Enterobacteriaceae
resistant to colistin, which is one of the few drugs active
against MDR Gram-negative bacteria.
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